Non-opioid drug developer Adolore Biotherapeutics has licensed a portfolio of biotechnologies targeting various types of pain from the University of Miami.
The portfolio includes DNA coding sequences and protein products developed at the university that suppress somatosensory neuronal excitability to treat chronic pain, including nociceptive, inflammatory, and neuropathic pain.
Through the exclusive license agreement, Adolore plans to enhance its development pipeline of novel carbonic anhydrase-8 variants (CA8) as gene therapies for localized treatment of chronic pain.
Under the terms of the agreement, the University of Miami will become a shareholder in Adolore and will receive an upfront payment in addition to certain clinical, regulatory and sales milestone payments, as well as royalties on sales of products resulting from the license.
Source: Access Wire
